Across TCGA pan-cancer cohorts, RPL21P17 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of RPL21P17’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where RPL21P17 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL21P17 is over-expressed in tumor, although a few such as UCEC and PAAD show the opposite, repressed pattern.

UCEC, PAAD, and BLCA are the cancer types where RPL21P17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL21P17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	−0.284	.015	2	view →
PAAD	Male	All	−0.280	.042	2	view →
BLCA	All	All	−0.161	.026	2	view →
THCA	Female	All	−0.130	.010	2	view →
LUAD	Female	II,III,IV	−0.232	.009	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: RPL21P17 RNA expression & survival · all RPL21P17 data types